Skip to content
Search

Latest Stories

Virus testing system hit by Roche supply issues

UK's Covid-19 testing system, already struggling with a surge in new cases, was facing fresh disruption on Wednesday (Oct 7) after Swiss pharmaceutical giant Roche said problems at a new warehouse had delayed the dispatch of some products.

Roche is one of the main suppliers of diagnostic tests to the NHS Test and Trace programme, which only days ago was hit by a technical glitch that delayed the reporting of 15,000 positive results.


Roche said the delay in dispatching some of its diagnostic products to the NHS was caused by unforeseen problems that arose during a switch from an old warehouse to a new UK distribution centre in September.

“We deeply regret that there has been a delay in the dispatch of some products and apologise to any of our customers who have been impacted,” Roche said in a statement.

“We are prioritising the dispatch of Covid-19 PCR and antibody tests and doing everything we can to ensure there is no impact on the supply of these to the NHS,” the company added, without specifying whether other products were affected.

Allan Wilson, president of Britain’s Institute of Biomedical Science, said Roche was a major supplier of materials such as reagents needed for routine blood tests, coagulation tests and in cancer diagnostics, as well as COVID-related materials.

“So it’s fair to say that laboratories are already running into supply problems,” Wilson said during an interview on BBC Radio 4. “We’re being very innovative in what we do, and we’re moving stuff around between laboratories, within the NHS, to make sure that all critical tests are fulfilled.”

Wilson said materials would be rationed when appropriate and the NHS was working closely with Roche to try and plug any gaps in the testing pathway.

Roche said staff at the new facility were working day and night to resolve the issue as soon as possible, and that extra staff had been recruited to help.

Days or weeks

The timing of Roche’s problems could hardly be worse for Britain, which has seen a surge in new coronavirus infections in September and the testing system struggling to meet demand.

Wilson said a significant drop in Roche’s capacity could potentially have a major impact on NHS Test and Trace.

“The key to this, we’re not sure the duration of this, we’re hearing days or weeks. If it’s days, it will probably have minimal impact, but if it’s weeks, then yes, that could have a considerable impact on our ability to deliver tests across the whole gambit of diagnostic tests in the UK,” he said.

International Trade secretary Liz Truss said the problem did not appear to be causing delays in the Test and Trace programme at this point.

“There’s no evidence that those tests have been delayed,” Truss told Sky News.

However, British media reported the problem was already causing disruption, with hospital managers unsure whether expected deliveries of swabs and reagents would materialise.

The BBC quoted Tom Lewis, lead clinician for pathology at North Devon District Hospital in southwest England, as saying the hospital had already sent out instructions to halt all non-urgent blood tests in the community.

Lewis said the hospital would run out of swabs in three to four days if the non-urgent tests were not rationed.

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less